Original InvestigationMultiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This work was founded by an Investigator-Initiated research grant from Bristol-Myers Squibb (to Dr. Chirinos) and National Institutes of Health (NIH) grant R01HL088577 (to Dr. Cappola). Dr. Chirinos is supported by NIH grants R01-HL 121510-01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874-01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck and Bayer; has received research grants from the National Institutes of Health, American College of Radiology Network, Fukuda-Denshi, Bristol-Myers Squibb, and Microsoft; and he is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of HFpEF and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in HFpEF. Drs. Zhao, Basso, Cvijic, Spires, Wang, and Seiffert are employees of and own stock in Bristol-Myers Squibb. Drs. Li, Yarde, and Gordon are employees of Bristol-Myers Squibb. Dr. Zamani is supported by grant K23-HL-130551; and has been a consultant for Vyaire. Dr. Margulies has received research grants from Merck, Sanofi, GlaxoSmithKline, AstraZeneca, and Luitpold; and has received consulting honoraria from Merck, GlaxoSmithKline, and Luitpold. Dr. Car is an employee and stockholder of Bristol-Myers Squibb; and is a future employee and stock holder of Agios Pharmaceuticals. Dr. Moore is supported by NIH grant LM010098. Dr. Cappola has received research funding from Bristol-Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- ∗
Drs. Chirinos and Olenko have contributed equally to this work.